Dyadic International, Inc. · NASDAQ:DYAI
Dyadic International — Q2 2026 Earnings Presentation
14 slides from Dyadic International's earnings presentation, Aug 12, 2026
Slide 1: Engineering Proteins That Power Progress
Engineering Proteins That Power Progress LIFE SCIENCES FOOD & NUTRITION BIOINDUSTRIAL Scalable protein solutions across Life Sciences, Food & Nutrition, and BioIndustrial markets. BIO International Convention 2026 1
Slide 2: Recombinant Solutions for Today’s Market
Recombinant Solutions for Today’s Market Global demand for animal-free proteins is accelerating while existing systems face critical constraints. Current Market Challenges The Dyadic Advantage High biologics manufacturing costs Faster development cycles ● Expensive mammalian cell production Stable s
Slide 3: Commercial Ready Platforms
Commercial Ready Platforms Recombinant solutions supporting scalable recombinant protein production. ADVANCED BIOLOGICS BIOINDUSTRIAL & NUTRITION C1 Platform Dapibus Platform Best Fit Best Fit Therapeutics • Vaccines • Complex Biologics Food & Nutrition • Functional proteins Cell culture application
Slide 4: Why Dyadic is Different
Why Dyadic is Different Microbial production systems combining speed, scalability and cost efficiency for modern recombinant protein manufacturing. Rapid strain development High productivity Stable strains in ~7 weeks Fast growth and high-yield expression Secreted protein expression Commercial scala
Slide 5: Platform Advantages at Commercial Scale
Platform Advantages at Commercial Scale Dyadic’s microbial expression platforms combine scalability and economics with mammalian-like capabilities. FASTER DEVELOPMENT HIGH PRODUCTIVITY LOWER COGS COMMERCIAL SCALE FLEXIBLE MANUFACTURING 5 Technology platforms engineered for scalable commercial execut
Slide 6: Biopharmaceutical Applications of the C1 Platform
Biopharmaceutical Applications of the C1 Platform High-yield production of complex biologics Advanced expression and glycoengineering capabilities supporting next-generation biologics. 6
Slide 7: Regulatory & Clinical Readiness
Regulatory & Clinical Readiness Designed for Biopharmaceutical Development Safe Reliable Compliant Scalable 7
Slide 8: Demonstrated Performance for Vaccines & Antibodies
Demonstrated Performance for Vaccines & Antibodies Faster development. Commercially relevant productivity High Yield Humanized Glycosylation Commercial Scale GMP Compatible 8
Slide 9: From Research Reagents to Therapeutic Biologics
From Research Reagents to Therapeutic Biologics One scalable production platform. Multiple product categories. Expanding value creation opportunities Reagents → Advanced Biologics LEVEL 1 LEVEL 2 LEVEL 3 LEVEL 4 Clinical Experience Human clinical program and vaccine dev activities. Regulatory Readin
Slide 10: Integrated Gene-to-Product Platform Workflow
+ Integrated Gene-to-Product Platform Workflow GENE STRAIN ENG PROCESS DEV SCALE-UP MANUFACTURING SUPPLY Dyadic Fermbox Joint Offering UPSTREAM INNOVATION MANUFACTURING EXECUTION INTEGRATED SERVICES ● Strain engineering ● Research & development ● Strain development ● Expression optimization ● Scale
Slide 11: Commercial Product Portfolio
Commercial Product Portfolio Animal-free recombinant proteins and enzymes available today 11
Slide 12: Proven Commercialization Pathway
Proven Commercialization Pathway From engineered cell line to commercial product launch in <24 months LICENSE DEVELOP SCALE LAUNCH 12 Technology platforms engineered for scalable commercial execution.
Slide 13: Let’s Explore What’s Possible
Let’s Explore What’s Possible Whether organizations need products, manufacturing support or strategic collaboration, Dyadic and Fermbox offer flexible paths to partnership. BUY BUILD PARTNER Commercial Products Custom Development Licensing & Manufacturing Immediate access to off-the-shelf Innovative
Slide 14: Thank You!
Thank You! info@dyadic.com